Heyder Omran Selected Research

Heyder Omran Research Topics

14	Atrial Fibrillation 01/2021 - 10/2002
8	Hemorrhage 03/2019 - 09/2003
7	Stroke (Strokes) 12/2023 - 04/2002
4	Thromboembolism 02/2015 - 09/2003
3	Renal Insufficiency (Renal Failure) 09/2011 - 10/2007
3	Intracranial Embolism 05/2006 - 09/2004
2	Thrombosis (Thrombus) 02/2015 - 10/2007
2	Thrombocytopenia (Thrombopenia) 06/2009 - 10/2007
2	Body Weight (Weight, Body) 02/2009 - 10/2007
2	Heart Failure 01/2004 - 10/2003
1	Transient Ischemic Attack 01/2020
1	Chronic Kidney Failure (Chronic Renal Failure) 03/2019
1	Venous Thromboembolism 02/2015
1	Acute Coronary Syndrome 02/2015
1	Myocardial Infarction 07/2012
1	Embolism (Embolus) 07/2012
1	Fatigue 01/2004
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2004
1	Coronary Artery Disease (Coronary Atherosclerosis) 10/2003
1	Coronary Disease (Coronary Heart Disease) 10/2003
1	Hypersensitivity (Allergy) 09/2003
1	Intracranial Aneurysm (Cerebral Aneurysm) 09/2003
1	Ventricular Tachycardia 08/2003
1	Tachycardia (Tachyarrhythmias) 08/2003

7	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 02/2015 - 06/2006
5	Heparin (Liquaemin)FDA LinkGeneric 02/2015 - 06/2006
4	Warfarin (Coumadin)FDA LinkGeneric 12/2016 - 04/2002
4	Enoxaparin (Lovenox)FDA LinkGeneric 06/2009 - 08/2003
3	AnticoagulantsIBA 01/2020 - 10/2007
2	Phenprocoumon (Liquamar)FDA Link 02/2009 - 08/2003
2	Ribose (D-Ribose)IBA 01/2004 - 10/2003
1	Contrast MediaIBA 03/2019
1	Coloring Agents (Dyes)IBA 03/2019
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 02/2016
1	Fondaparinux (Arixtra)FDA Link 02/2015
1	Factor Xa InhibitorsIBA 02/2015
1	Retinaldehyde (Retinal)IBA 07/2012
1	CreatinineIBA 06/2009
1	Vitamin K FDA Link 06/2006

19	Therapeutics 12/2023 - 04/2002
5	Contraindications 01/2021 - 09/2003
3	Electric Countershock (Cardioversion) 02/2015 - 10/2002
1	Secondary Prevention 01/2020
1	Catheters 09/2017
1	Drug Therapy (Chemotherapy) 10/2003
1	Defibrillators (Defibrillator) 08/2003
1	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 08/2003